Latuda

Lurasidone
Clinical data


Trade names	Latuda
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a611016
License data	US DailyMed: 88a244d1-eddb-499c-bee2-e1f49056e78f
Pregnancy category	AU: B1 US: B (No risk in non-human studies)
Routes of administration	Oral
ATC code	N05AE05 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only US: ℞-only
Pharmacokinetic data
Bioavailability	9–19% (oral)
Metabolism	Hepatic (CYP3A4-mediated)
Biological half-life	18 hours
Excretion	Faecal (~80%), renal (~9%)
Identifiers
IUPAC name (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione
Synonyms	SM-13,496
CAS Number	367514-87-2
PubChem (CID)	213046
IUPHAR/BPS	7461
ChemSpider	184739
UNII	22IC88528T^Y
ChEBI	CHEBI:70735^Y
ChEMBL	CHEMBL1237021
ECHA InfoCard	100.225.187
Chemical and physical data
Formula	C₂₈H₃₆N₄O₂S
Molar mass	492.68 g/mol
3D model (Jmol)	Interactive image
Specific rotation	[α]²⁰_D −59°
Melting point	176 to 178 °C (349 to 352 °F)
Solubility in water	45 mg/mL (20 °C)
SMILES C1CC[C@H]([C@@H](C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)[C@H]6[C@@H]7CC[C@@H](C7)[C@H]6C5=O
InChI InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1 Key:PQXKDMSYBGKCJA-CVTJIBDQSA-N

Lurasidone /lɜːr.ˈræ.sɪ.doʊn/ (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the USA. It has been approved for treatment of schizophrenia by the FDA since 2010. In the USA since 2013, it is also approved for the treatment of depressive episodes associated with bipolar I disorder as well as bipolar II disorder in adults when used alone or in combination with lithium, valproate, or lamotrigine.

Lurasidone is FDA approved for the treatment of schizophrenia since 2010 and depressive episodes associated with bipolar I disorder since 2013. It received regulatory approval in the UK in September 2014. In October 2014, NHS Scotland advised use of lurasidone for schizophrenic adults who have not seen improvements with previous antipsychotics due to problems that arise from weight gain or changes in metabolic pathways when taking other medications. It received EMA approval on January 24, 2014. It was launched in Canada for the treatment of schizophrenia in September 2012, Health Canada giving their Summary Basis of Decision (SBD) as favourable on October 15, 2012. European Commission has granted a marketing authorization for once-daily oral lurasidone for the treatment of schizophrenia in adults. It is approved for use in the EU.

...
Wikipedia